Nivolumab Plus Cabozantinib vs Sunitinib for First-Line Treatment of Advanced Renal Cell Carcinoma (aRCC): 3-Year Follow-Up From the Phase 3 CheckMate 9 ER Trial (vol 41, pg 603, 2023)

被引：0
|
作者：
Motzer, Robert J.
机构：
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 41卷 / 21期
关键词：
D O I：
10.1200/JCO.23.00901
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：3767 / 3767
页数：1
相关论文
共 50 条
  • [31] Partitioned overall survival: Comprehensive analysis of survival states over 4 years in CheckMate 9ER comparing first-line nivolumab plus cabozantinib versus sunitinib in advanced renal cell carcinoma (aRCC)
    Mantia, Charlene
    Jegede, Opeyemi
    Viray, Hollis
    Atkins, Michael B.
    Rosenblatt, Lisa
    Yin, Xin
    McDermott, David F.
    Regan, Meredith M.
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [32] Increasing combination possibilities for first-line treatment of metastatic clear cell renal cell carcinoma with nivolumab plus cabozantinib Results of the CheckMate-9ER trial
    Oing, Christoph
    Bokemeyer, Carsten
    ONKOLOGE, 2021, 27 (02): : 168 - 171
  • [33] Nivolumab plus ipilimumab versus sunitinib in first-line treatment for advanced renal cell carcinoma: extended follow-up of efficacy and safety results from a randomised, controlled, phase 3 trial (vol 20, pg 1370, 2019)
    Motzer, R. J.
    Rini, B., I
    McDermott, D. F.
    LANCET ONCOLOGY, 2020, 21 (06): : E304 - E304
  • [34] Nivolumab plus ipilimumab versus sunitinib in first-line treatment for advanced renal cell carcinoma: extended follow-up of efficacy and safety results from a randomised, controlled, phase 3 trial (vol 20, pg 1370, 2019)
    Motzer, R. J.
    Rini, B., I
    McDermott, D. F.
    LANCET ONCOLOGY, 2020, 21 (11): : E518 - E518
  • [35] Nivolumab plus ipilimumab versus sunitinib in first-line treatment for advanced renal cell carcinoma: extended follow-up of efficacy and safety results from a randomised, controlled, phase 3 trial (vol 20, pg 1370, 2019)
    Motzer, R. J.
    Rini, B., I
    McDermott, D. F.
    LANCET ONCOLOGY, 2019, 20 (10): : E559 - E559
  • [36] JAVELIN renal 101: a phase 3 study of avelumab in combination with axitinib vs sunitinib as first-line treatment for patients with advanced renal cell carcinoma (aRCC)
    Choueiri, Toni K.
    Rini, Brian I.
    Cosgriff, Thomas
    Miyake, Hideaki
    Vogelzang, Nicholas J.
    Kannourakis, George
    Mariani, Mariangela
    Chiruzzi, Chiara
    Albiges, Laurence
    Haanen, John B.
    Larkin, James
    Atkins, Michael B.
    Schmidinger, Manuela
    Magazzu, Domenico
    Di Pietro, Alessandra
    Motzer, Robert J.
    BJU INTERNATIONAL, 2016, 118 : 29 - 30
  • [37] Cost-Effectiveness of Nivolumab Plus Cabozantinib Versus Sunitinib as a First-Line Treatment for Advanced Renal Cell Carcinoma in the United States
    Li, SiNi
    Li, JianHe
    Peng, LiuBao
    Li, YaMin
    Wan, XiaoMin
    FRONTIERS IN PHARMACOLOGY, 2021, 12
  • [38] JAVELIN renal 101: A randomized, phase III study of avelumab plus axitinib vs sunitinib as first-line treatment of advanced renal cell carcinoma (aRCC)
    Motzer, R. J.
    Penkov, K.
    Haanen, J. B. A. G.
    Rini, B. I.
    Albiges, L.
    Campbell, M. T.
    Kollmannsberger, C. K.
    Negrier, S.
    Uemura, M.
    Lee, J. L.
    Gurney, H.
    Berger, R.
    Schmidinger, M.
    Larkin, J.
    Atkins, M. B.
    Wang, J.
    Robbins, P. B.
    Chudnovsky, A.
    Di Pietro, A.
    Choueiri, T. K.
    ANNALS OF ONCOLOGY, 2018, 29 : 724 - 724
  • [39] Patterns of progression in patients treated with nivolumab plus ipilimumab (NIVO plus IPI) versus sunitinib (SUN) for first-line treatment of advanced renal cell carcinoma (aRCC) in CheckMate 214.
    Tannir, Nizar M.
    Motzer, Robert J.
    Albiges, Laurence
    Plimack, Elizabeth R.
    George, Saby
    Powles, Thomas
    Donskov, Frede
    Rini, Brian, I
    Grunwald, Viktor
    Hammers, Hans J.
    Choueiri, Toni K.
    Gurney, Howard
    Tykodi, Scott S.
    Porta, Camillo
    Burotto, Mauricio
    Tomita, Yoshihiko
    Lee, Chung-Wei
    Tang, Chad
    McDermott, David F.
    McKay, Rana R.
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (06)
  • [40] Nivolumab versus everolimus in advanced renal cell carcinoma: Japanese subgroup 3-year follow-up analysis from the Phase III CheckMate 025 study
    Tomita, Yoshihiko
    Fukasawa, Satoshi
    Shinohara, Nobuo
    Kitamura, Hiroshi
    Oya, Mototsugu
    Eto, Masatoshi
    Tanabe, Kazunari
    Saito, Mitsuru
    Kimura, Go
    Yonese, Junji
    Yao, Masahiro
    Uemura, Hirotsugu
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2019, 49 (06) : 506 - 514
12345